Company: NCEL
Filing Date: 2025-09-04
Form Type: 425
Source: 0001213900-25-084283
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-09-04
Form: 425
Chunk 3
---
 Kadimastem’s broader diabetes program, that
continued progress on strong, defensible intellectual property is essential as Kadimastem works toward clinical development and
future patient access, that each new territory that grants patents validates the uniqueness of Kadimastem’s technology and
provides important protection as Kadimastem advance toward clinical development and that the patent reinforces Kadimastem’s
long-term strategy to bring a potentially curative cell therapy to patients worldwide. These forward-looking statements and their
implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ materially from those described in the forward-looking
statements: risks related to the companies’ ability to complete the merger on the proposed terms and schedule, including risks
and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties
related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses
resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement
or completion of the proposed merger; changes in technology and market requirements; either or both companies may encounter delays
or obstacles in launching and/or successfully completing their clinical trials; the companies’ products may not be approved by
regulatory agencies; their technologies may not be validated as they progress and their methods may not be accepted by the
scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge is essential
to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by the
companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally
good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials;
the companies’ patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact
either or both of the companies; inability to timely develop and introduce new technologies, products and applications; and loss of
market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate
products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law,
neither Kadimastem nor NLS